Ibalgin (Cream) Instructions for Use
Marketing Authorization Holder
Zentiva, a.s. (Czech Republic)
ATC Code
M02AA13 (Ibuprofen)
Active Substance
Ibuprofen (Rec.INN registered by WHO)
Dosage Form
| Ibalgin | Cream for external use 5%: 30 g or 50 g tubes |
Dosage Form, Packaging, and Composition
Cream for external use 5% of emulsion type, white or almost white in color.
| 1 g | |
| Ibuprofen | 50 mg |
Excipients: witepsol (hydrogenated fat), medium saturated triacetyl glycerides (miglyol 812), cetylstearyl alcohol, ethoxylated C12-C16 alcohols (sovvasol 2430), monoglycerides of saturated higher fatty acids (polinol A), carbomer 940, trolamine, methylparaben, propylparaben, propylene glycol, purified water.
30 g – aluminum tubes (1) – cardboard packs.
50 g – aluminum tubes (1) – cardboard packs.
Clinical-Pharmacological Group
NSAIDs for external use
Pharmacotherapeutic Group
NSAID
Pharmacological Action
The drug has a local analgesic and anti-inflammatory effect and eliminates inflammatory edema. The key element in the mechanism of the specific action of ibuprofen is the inhibition of prostaglandin synthesis due to the inhibition of cyclooxygenases type 1 and 2.
Pharmacokinetics
After application of the cream to the skin, Ibuprofen penetrates well into the subcutaneous tissue. The Cmax of ibuprofen in plasma after topical application of 5 g of cream (corresponding to 250 mg of ibuprofen) is about 100 ng/ml, which is about 0.5% of that after oral administration of a similar dose.
Indications
- Diseases of the musculoskeletal system: rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, osteoarthritis of peripheral joints and spine, low back pain;
- Muscle pain of rheumatic and non-rheumatic origin;
- Traumatic soft tissue injury.
ICD codes
| ICD-10 code | Indication |
| M05 | Seropositive rheumatoid arthritis |
| M07 | Psoriatic and enteropathic arthropathies |
| M15 | Polyosteoarthritis |
| M42 | Spinal osteochondrosis |
| M45 | Ankylosing spondylitis |
| M54.5 | Low back pain |
| M79 | Other soft tissue disorders, not elsewhere classified |
| M79.1 | Myalgia |
| T14.0 | Superficial injury of unspecified body region (including abrasion, bruise, contusion, hematoma, bite of nonvenomous insect) |
| T14.3 | Dislocation, sprain and strain of joint and ligament of unspecified body region |
| ICD-11 code | Indication |
| EH92 | Dermatoses provoked by friction or mechanical impact |
| EH92.1 | Blister due to friction |
| FA05 | Polyosteoarthritis |
| FA20.0 | Seropositive rheumatoid arthritis |
| FA21.Z | Psoriatic arthritis, unspecified |
| FA85.Z | Defects of vertebral end-plates, unspecified |
| FA92.0Z | Ankylosing spondylitis, unspecified |
| FB56 | Specified soft tissue diseases, not elsewhere classified |
| FB56.2 | Myalgia |
| ME84.2Z | Low back pain, unspecified |
| ND56.0 | Superficial injury of unspecified body region |
| ND56.3 | Dislocation, sprain or strain of unspecified body region |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
For external use only. Apply a 4-10 cm strip of cream onto the skin over the affected area.
Rub in gently with light movements until fully absorbed.
Apply the cream 2-3 times per day at regular intervals.
For severe pain or extensive hematomas, you may cover the treated area with a protective, air-permeable bandage.
Wash hands thoroughly after each application, unless the hands are the treated area.
Avoid contact with eyes, mucous membranes, and open or damaged skin.
Do not dilute or mix this cream with other topical products.
The duration of treatment must not exceed 5-7 days without medical consultation.
Discontinue use and consult a physician if symptoms persist or worsen.
Do not apply under occlusive dressings unless specifically directed by a doctor.
Adverse Reactions
Possible allergic reactions to the components of the drug in the form of redness, itching of the skin, swelling, burning sensation, skin rash.
With long-term use, the development of systemic side effects characteristic of NSAIDs is possible.
If signs of allergic reactions appear, the use of the drug should be discontinued.
Contraindications
- History of bronchial asthma attacks and other allergic manifestations associated with the use of acetylsalicylic acid or other NSAIDs;
- Weeping dermatoses;
- Eczema;
- Infected abrasions and wounds;
- Children under 12 years of age;
- Pregnancy, lactation period;
- Hypersensitivity to the main active substance or to other components of the drug.
The drug should not be applied to an open wound surface or damaged skin surface. Avoid getting the cream into the eyes and mucous membranes.
Use in Pregnancy and Lactation
Contraindication: pregnancy, lactation period.
Pediatric Use
Contraindication: children under 12 years of age.
Special Precautions
It is not recommended to dilute or mix Ibalgin cream with other topical products.
Overdose
Cases of overdose have not been described.
In case of accidental ingestion of the drug or application to damaged skin, nausea and vomiting may occur; it is necessary to perform gastric lavage and consult a doctor; if necessary, symptomatic treatment is carried out.
Storage Conditions
At a temperature of 10-25°C (-13°F) in a dry place out of the reach of children.
Shelf Life
Shelf life – 2 years.
Dispensing Status
The drug is approved for use as an over-the-counter product.
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer